Natera, Inc. (NASDAQ:NTRA) is Eagle Health Investments LP’s Largest Position

Eagle Health Investments LP trimmed its holdings in shares of Natera, Inc. (NASDAQ:NTRA) by 21.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 339,764 shares of the medical research company’s stock after selling 91,550 shares during the quarter. Natera accounts for approximately 13.2% of Eagle Health Investments LP’s investment portfolio, making the stock its largest holding. Eagle Health Investments LP owned approximately 0.26% of Natera worth $53,785,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in NTRA. Blue Trust Inc. boosted its stake in shares of Natera by 104.3% during the fourth quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 97 shares in the last quarter. Versant Capital Management Inc lifted its holdings in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock worth $34,000 after purchasing an additional 166 shares during the period. EverSource Wealth Advisors LLC grew its position in Natera by 372.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock worth $52,000 after purchasing an additional 261 shares during the period. Principal Securities Inc. boosted its position in Natera by 20.7% in the 4th quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after purchasing an additional 59 shares in the last quarter. Finally, True Wealth Design LLC purchased a new stake in shares of Natera during the 3rd quarter worth about $57,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Natera

In other Natera news, insider John Fesko sold 663 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $177.77, for a total value of $117,861.51. Following the sale, the insider now directly owns 156,044 shares of the company’s stock, valued at $27,739,941.88. This trade represents a 0.42 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Steven Leonard Chapman sold 78,553 shares of the stock in a transaction dated Wednesday, January 22nd. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 306,797 shares of company stock valued at $48,940,883 over the last quarter. Company insiders own 7.60% of the company’s stock.

Natera Stock Down 3.1 %

NTRA opened at $149.84 on Thursday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The company has a market cap of $20.26 billion, a price-to-earnings ratio of -85.14 and a beta of 1.80. The business’s fifty day moving average is $160.29 and its two-hundred day moving average is $150.55.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to the consensus estimate of $447.91 million. Analysts anticipate that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Wall Street Analyst Weigh In

NTRA has been the topic of several research analyst reports. Guggenheim lifted their price objective on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Friday, January 17th. JPMorgan Chase & Co. boosted their price objective on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a report on Friday, December 13th. Barclays assumed coverage on Natera in a report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price for the company. BTIG Research reiterated a “buy” rating on shares of Natera in a research note on Friday, February 28th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $180.00 price target on shares of Natera in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $178.12.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.